	Application No.	Applicant(s)
Notice of Allowability	10/727,168	ALLERTON ET AL.
	Examiner	Art Unit
	Kamal A. Saeed	1626
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to communication filed on 6/15/07.		
2. The allowed claim(s) is/are 8 now renumbered as 1.		
 3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. 		
	÷	
·		·
	· ·	
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. Notice of Informal	Potent Application
Notice of Profites Cited (PTO-692) Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summan	
	Paper No./Mail Da	ate
 Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 6/15/07 	7. Examiner's Amend	lment/Comment
4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Statem	ent of Reasons for Allowance
of Biological Material	9. 🔲 Other	
		·
	•	
		•

Application/Control Number: 10/727,168

Art Unit: 1626

DETAILED ACTION

Claims 1-7 and 9-22 have been canceled. Therefore, only claim 8 is currently pending in this application.

RCE

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on June 15, 2007 has been entered.

Information Disclosure Statement

The Information Disclosure Statement filed on June 09, 20 is in compliance with 37 C.F.R. 1.97, and was considered by the examiner. Please refer to Applicant's copies of the 1449 submitted herewith.

Previous Rejections

Claim 8 was rejected under 35 U.S.C. 103(a) as being obvious over Fisher, et al U.S. Patent No. 5,077,290.

Reasons for Allowance

Applicants argument and Declaration filed under 37 CFR 1.132 was found persuasive in overcoming the 103 (a) rejection. The test results of the compound claimed in this application and the closest prior art showed that the claimed compounds have stronger activity at D3

Application/Control Number: 10/727,168

Art Unit: 1626

receptor in both a binding and a functional assay than the more active enantiomer of the prior art.

Therefore, claim 8 is allowable over the prior art.

Any comments considered necessary by applicant must be submitted no later than the payment issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submitions should be clearly labeled "Comments on Statement for Reasons for Allowance."

Any comments considered necessary by applicant must be submitted no later than the payment issue fee and, to avoid processing delays, should preferably accompany the issue fee.

Such submitions should be clearly labeled "Comments on Statement for Reasons for Allowance."

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kamal A Saeed whose telephone number is (571) 272-0705. The examiner can normally be reached on M-T 7:00 AM- 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Joseph K. McKane, can be reached at (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300. Please note this is the central FAX number for all official correspondence.

Communication via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signiture, may be used by applicant and should be addressed to [joseph.mckane@uspto.gov]. All Internet e-mail communications will be made of record in the application file. PTO employees will not communicate with applicant via Internet

Application/Control Number: 10/727,168

Art Unit: 1626

Page 4

Osacad

e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive data could be identified unless there is of record an express waiver of the confidentiality requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG 89.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR only. For more information about the pair system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197.

KAMAL A. SAEED, PH.D. PRIMARY EXAMINER